Professor Tavakoli intends to introduce and evaluate the VibroSense Meter® II in ongoing clinical studies on people with diabetes. The aim is to investigate whether the VibroSense instrument can be a tool for early and reliable detection of nerve damage caused by diabetes (Diabetic Peripheral Neuropathy).

For VibroSense, the collaboration is expected to provide the company with additional knowledge and clinical data that can be used to increase interest in the application Diabetic Foot Screening.

Within research, there is an overwhelming consensus that today's clinical methods for diagnosing diabetic neuropathy are far too inferior. For people living with diabetes and the health care, this has serious consequences both in terms of personal suffering and astronomical costs. The need for better diagnostic methods is therefore deemed urgent.

"The collaboration with Professor Tavakoli is a great success that can mean a lot in gaining acceptance for the company's instruments and technology among world-leading researchers in diabetic neuropathy. Professor Tavakoli is a respected member of Neurodiab, which is an important research group with special responsibility for promoting research and education in diabetic neuropathy",  says Hans Wallin, CEO of VibroSense Dynamics AB.

"The clinical care of the diabetic foot today is inadequate, which is largely due to the lack of reliable methods to detect peripheral neuropathy. It is therefore of great interest to evaluate the instrument VibroSense Meter® II clinically to investigate whether it is a tool for Screening of the diabetic foot, which also can facilitate development of new treatment regimens", says Professor Mitra Tavakoli, Exeter Center of Excellence for Diabetes Research.

Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.se

"The new Gold Standard for reliable
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB develops and sells medical technology products and services to facilitate diagnosis of nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies.

The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers. Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.

About E Exeter Center of Excellence for Diabetes Research
The Exeter Center of Excellence for Diabetes Research (EXCEED) is the home of Exeter's world-leading diabetes research team. Our unique expertise, pioneering research, and cutting-edge innovation in technology, is challenging the way scientists approach diabetes research and transforming patient care throughout the world.

EXCEED's revolutionary diabetes research and outstanding postgraduate and professional education are underpinned by our expertise in genomics and cutting-edge innovation in technology.

In type 1, type 2 and monogenic diabetes, our research takes a precision medicine approach, and is embedded in clinical practice. This means our discoveries are swiftly implemented to benefit people with diabetes.